Report from India - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Report from India
India's drug pricing authority increased the retail costs of certain domestically manufactured drugs, but not those of imported drug products. Pharma is asking why.

Pharmaceutical Technology
Volume 35, Issue 6, pp. 18-20

The global response

Imported insulin brands of multinational firms, such as Indianapolis-headquartered Eli Lilly, Denmark's Novo Nordisk, and France's Sanofi, make up two-thirds of the insulin market share in India. Objecting to NPPA's price hike, Eli Lilly is taking the issue to local courts and Novo Nordisk is seeking a governmental review of NPPA's decision.

Other global drug manufacturers are likely to follow suit, but Pfizer's Mumbai headquarters is trying a different approach. Pfizer has been seeking a price increase in India for its imported drug Medrol (the generic version is methylprednisolone) used to treat allergic disorders and arthritis. NPPA denied the company's request, and, says Kewal Handa, managing director of Pfizer Limited, an open dialogue with the concerned officials is the best medium to adopt in this instance. "If the NPPA reduces prices, we cut costs. If it increases drug prices, multinationals should also benefit.'' Although he did not specifically comment on Medrol, Handa says that multinationals should engage in dialogue with Indian authorities, "either personally with the government, or use the good offices of the association that caters to multinational drug majors to address their grievances.''

The ongoing battle

Incidentally, it is not just insulin that is under scrutiny. Branded breast-cancer medications that contain the ingredient letrozole are also being reviewed, as are a host of other imported medications. Meanwhile, NPPA is still waiting for global drug manufacturers to share certain details about their imported brands meant for the local market. One NPPA official says, "They have not acceded to our requests."

Table I: Price differences among anticancer drugs in India.
The official added that several importers have been asked to verify with details whether the price of the drug in India was reasonable, given that generic versions of the same drug sold by domestic firms were retailing at one-tenth of the price. In fact, NPPA has found many significant price variations among different brands of the same medicine sold in the country (see Table I).

G.G. Nair, past president of the Indian Drug Manufacturers Association, says all imported medicines follow a price-control formula. "There are two categories of imported medicine: patented in India and not patented in India. Another category is that of equivalent drugs available in the local market and not available [in the local market]. If it is not available, multinationals can fix any price and import into India and the NPPA can't intervene,'' he says. However, because the Indian rupee appreciation factor is calculated to determine the domestic cost of a medicine, Nair says that NPPA has initiated measures to ensure that importers of medicines pass on the benefits of cheaper imports, on account of the stronger rupee, to consumers.

In the meantime, the battle over pricing continues. In April 2011, NPPA issued notices to multinational as well as domestic drug companies for overcharging consumers, claiming arrears of $521 million through Jan. 31, 2011. Of this amount, $46 million was recovered. Several cases are still in litigation.

—A. Nair is a freelance writer based in Mumbai


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here